欧洲肝病学会会议上关于dv-601的消息

benben00

Poster PresentationsSession Title: Category 07c: Viral Hepatitis B & D: Clinical (therapy, new compounds, resistance)
Presentation Date: 01 APR, 2011
TREATMENT OF CHRONIC HEPATITIS B INFECTION WITH DV-601, A THERAPEUTIC VACCINE

M. Spellman1*, J.T. Martin2
1Clinical Research and Development, 2Dynavax Technologies, Berkeley, CA, USA. *[email protected]

Therapeutic vaccines may promote the resolution of chronic hepatitis B infection (CHB) through the stimulation of specific cytotoxic T-lymphocyte and B-cell antibody responses to dominant hepatitis B virus (HBV)-antigens. DV-601 is comprised of recombinant HBV surface antigen (HBsAg) and HBV core antigen (HBcAg), with adjuvant. In this initial dose-escalation study of DV-601 in treatment-naïve or treatment-tolerant adult patients with CHB, patients received 6 intramuscular doses of DV-601 (0.1, 0.25, or 0.5 mL) on Days 1, 15, 29, 57, 71, and 85. Of the 14 enrolled patients, 8 were HBV e-antigen positive and were treatment-naïve; 6 patients, all HBV e-antigen negative, had been treated with nucleoside analog(s) prior to enrolling in the study. Oral entecavir therapy was initiated (and other nucleoside analog therapy was discontinued, if applicable) prior to the first DV-601 injection, and was continued daily during the study. The primary objective was to assess the safety and tolerability of DV-601 by the evaluation of local and systemic adverse events to Day 99, including changes in laboratory analyses. Secondary objectives were to evaluate virological response and immunogenicity of DV-601 based on HBV viral load, and humoral and T cell immunological responses. Fourteen patients were enrolled and completed all injections of DV-601. Injection site reactions were generally short-lived and resolved without treatment; systemic injection reactions including fatigue, malaise, chills, and headache were transient and rarely required intervention. Reductions in HBV DNA, and s and e antigen are apparent in all dose groups, and antibodies to s and e antigens developed in the higher dose groups. All patients developed an HBV-specific lymphoproliferative response; an HBc-specific interferon-gamma T cell response was noted in 2 of 6 patients who were e-antigen positive and had received the highest dose of DV-601. DV-601 appears to be a safe and well-tolerated therapeutic vaccine for the treatment of CHB, and virological response is evident.

(6.合.彩).足球.篮球...各类投注开户下注

第一投注.现金网:招代理年薪10万以上:6668.cc

benben00

这个就是王震宇去开的会把

benben00

这个就是王震宇去开的会把

benben00

目前看不到具体的数据，但是可以看出，DV-601的耐受性不错，HBV dna 下降，在高剂量组中已经观察到s和e抗体的产生。
不管怎么说，总归看到了点希望

interdetect

等震宇兄回来问问他
不过震宇出了拉米外什么都不相信啊

买平安的

interdetect 发表于 2011-3-31 16:03
等震宇兄回来问问他
不过震宇出了拉米外什么都不相信啊

这个倒是对老王的异化，老王是首选拉米。没有“出了拉米外什么都不相信”。

lin12345

治疗性疫苗可能通过具体的细胞毒性T淋巴细胞和B细胞的抗体反应到显性乙型肝炎病毒（HBV）-抗原刺激对慢性乙型肝炎病毒感染（乙肝）的决议。的DV - 601是由基因重组乙肝病毒表面抗原（HBsAg）和乙肝病毒核心抗原（HBcAg的），与佐剂。在这个初始剂量升级的DV - 601的研究与治疗慢性乙型肝炎的治疗天真或​​耐成年患者，患者接受的日子1，15，29 6的DV - 601（0.1，0.25，或0.5毫升）肌肉注射剂量， 57，71和85。在14位病人中，8例乙肝病毒e抗原阳性，并治疗初治6例，所有乙肝病毒e抗原阴性，已与核苷类似物（s）之前的研究，研究对象对待。恩替卡韦治疗口腔开始（和其他核苷类似物治疗已经停止，如果适用）前第一的DV - 601注射液，并继续在研究日报。主要目的是评估的局部和全身不良事件评价的安全的DV - 601耐受到99日，包括实验室分析的变化。次要目标是评估的病毒学应答的DV - 601基于免疫原性乙肝病毒载量，免疫和体液免疫反应和T细胞。十四名患者参与并完成的DV - 601的所有注射​​。注射部位反应通常短暂的，未经处理解决;全身注射反应，包括疲劳，全身乏力，发冷，头痛等症状都是短暂的，很少需要干预。在HBV DNA的减少，而且S和E抗原是显而易见的各剂量组，并s和e抗原抗体在较高剂量组开发。所有患者开发的HBV特异性淋巴细胞增殖反应;一HBc阳性特定干扰素-γ的T细胞反应6例在2谁是e抗原阳性，并已收到的DV - 601最高剂量指出。的DV - 601似乎是一种安全，耐受性良好的治疗慢性乙型肝炎治疗性疫苗和病毒学反应可见一斑。

ybdn

interdetect 发表于 2011-3-31 16:03
等震宇兄回来问问他
不过震宇出了拉米外什么都不相信啊

你没有仔细看过置顶的王主任的拉米攻略，王主任除干扰素不爱用外（10多年前爱用），阿德、恩替等核苷药物都用，用的最多的是拉米。
很多人骂王主任只用拉米，其实是他们自己不长眼，不看原帖，人云亦云。